Last update April 27, 2024


Likely Compatibility

Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.

It is an angiotensin II receptor antagonist with actions similar to those of losartan. It is indicated in the treatment of hypertension. Oral administration once a day.

At latest update, relevant published data on excretion into breast milk were not found.

Its pharmacokinetic data (very large volume of distribution, moderately high molecular weight and high percentage of binding to plasma proteins) make it unlikely to pass into breast milk in clinically significant quantities.

It is one of the sartanes (ARBs) with the longest half-life and oral bioavailability (Tamargo 2006), making it one of the least indicated during breastfeeding. 

Reportedly, a newborn infant appeared with transient renal failure (kidney malfunction) whose mother had taken Telmisartan during pregnancy. (Pietrement 2003)

Until more data on this medication is available safer alternative drugs are preferred (Malachias 2016, Rowe 2013), especially in premature babies or during the neonatal period.


Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Telmisartan in other languages or writings:


Main tradenames from several countries containing Telmisartan in its composition:


Variable Value Unit
Oral Bioavail. 40 - 58 %
Molecular weight 515 daltons
Protein Binding 100 %
VD 6.9 l/Kg
pKa 3.62 -
Tmax 1 - 3 hours
24 hours


  1. Malachias MV, Figueiredo CE, Sass N, Antonello IC, Torloni MR, Bortolotto MRF L. 7th Brazilian Guideline of Arterial Hypertension: Chapter 9 - Arterial Hypertension in pregnancy Arq Bras Cardiol. 2016 Abstract Full text (link to original source)
  2. Rowe H, Baker T, Hale TW. Maternal medication, drug use, and breastfeeding. Pediatr Clin North Am. 2013 Feb;60(1):275-94. Abstract
  3. Boe.Ing. Telmisartan. Drug Summary. 2013 Full text (in our servers)
  4. AEMPS. Telmisartán. Ficha técnica. 2010 Full text (in our servers)
  5. Tamargo j, Caballero R, Gómez R, Núñez L, Vaquero M y Delpón E. Características farmacológicas de los ARA-II. ¿Son todos iguales?. Rev Esp Cardiol Supl. 2006;6:10C-24C. 2006 Full text (in our servers)
  6. Pietrement C, Malot L, Santerne B, Roussel B, Motte J, Morville P. Neonatal acute renal failure secondary to maternal exposure to telmisartan, angiotensin II receptor antagonist. J Perinatol. 2003 Abstract Full text (link to original source) Full text (in our servers)

Total visits


Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at

e-lactancia is a resource recommended by El Parto Es Nuestro of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM